Trial Profile
A Phase IB Study of the Combination of AZD6244 Hydrogen Sulfate (Selumetinib) and Cyclosporin A (CsA) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary) ; Ciclosporin
- Indications Cervical cancer; Colorectal cancer; Endometrial cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- 20 Mar 2024 Planned End Date changed from 7 Mar 2024 to 19 Mar 2025.
- 24 Jul 2018 Results published in the Cancer Research
- 15 Jun 2017 Status changed from recruiting to active, no longer recruiting.